Zimmer Biomet Holdings (ZBH) to Debut New Z1 Femoral Hip System and Clinical Data on G7® Acetabular System at 2024 AAHKS Annual Meeting

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/24/2026

1. SPCX
2. META
3. ABBV
4. SPY
5. FDX
6. IBM
7. NKE
8. MU
9. AWK
10. ACN

Go back to Zimmer Biomet Holdings (ZBH) to Debut New Z1 Femoral Hip System and Clinical Data on G7® Acetabular System at 2024 AAHKS Annual Meeting

Oppenheimer Reiterates Outperform Rating on Zimmer Biomet (ZBH)

October 30, 2024 4:28 PM EDT

Oppenheimer analyst Steven Lichtman reiterated an Outperform rating and $135.00 price target on Zimmer Biomet (NYSE: ZBH).

The analyst comments "3Q24 sales of $1.824B (+4.1% constant-currency) outpaced our/Street's $1.791B/$1.795B on less ERP headwind than expected and better than expected underlying performance, particularly in SET. Knees... More